Table 1 Expression of AM and AM receptors in tumours and their role on disease progression

Breast carcinoma

presence

Prot

lymph node metastasis

[138],[144]

Bladder urothelial cell carcinoma

>mRNA/Prot

[120]

Chromophobe renal carcinoma

>mRNA

[121]

<Prot

Clear-cell renal carcinoma

>mRNA

CLR and RAMP2

[118],[121]

Prot

Colorectal carcinoma

>mRNA

>CLR, RAMP2, RAMP3

progression

[119],[147],[148]

>Prot

Midgut tumour

>

progression

[108]

Anaplastic astrocytoma

<mRNA

[128],[131]

Glioma

>mRNA

progression

[127]

Glioblastoma

>mRNA

CLR, RAMP2 and RAMP3

[121],[128],[131]

Hepatocellular carcinoma

>mRNA

invasion and progression

[132],[133]

>Prot

Intraocular or orbital tumours

>mRNA

[139]

Leiomyoma

>Prot

[126]

ganglioneuroblastoma

>Prot

[129]

Neuroblastoma

>mRNA

differentiation

[129],[143]

>Prot

Bronchial neuroendocrine tumour

>

progression

[108]

Small cell lung carcinoma

<mRNA

[134],[141]

Non-small cell lung carcinoma

mRNA immunoreactivity was essentially weak

[134],[141]

Squamous cell carcinoma of the lungs

<mRNA

[134],[141]

Adenocarcinoma of the lung

mRNA

[134],[141]

Osteosarcoma

>

>mRNA / Prot

metastasis

[109]

Ovarian carcinoma

> mRNA / Prot

over-all survival

[123],[124],[142]

Positive Prognostic Factor

[149]

Endometrial carcinoma

>mRNA

progression

[125],[150]

<Prot

Pancreatic adenocarcinoma

>

>AM &CLR mRNA / Prot

CLR, RAMP1 and RAMP2

[110],[116],[122],[151]

Pancreatic insulinoma

>

>Prot

[110],[111]

Adrenocortical tumours

>

mRNA

[113],[135],[136]

Prot no detected

Pheochromocytoma

>

mRNA

CLR, RAMP1, RAMP2 and RAMP3

[114],[117],[129],[135]–[137],[152]

>Prot

Pituytary adenomas

>

>Prot

progression

[112],[130],[136],[145]

Plexiform neurofibroma

>

biomarker of transformation

[115]

Somatotropinoma

>mRNA

Knerr et al., [131])

Prolactinoma

mRNA

meningiomas

mRNA

Prostate

mRNA

high Gleason scores

[146],[153]

adenocarcinoma

Prot

Skin carcinomas

Prot

> CLR, RAMP2, and RAMP3

[78],[140]